Literature DB >> 30953918

Quantification of residual AEBSF-related impurities by reversed-phase liquid chromatography.

Cindy X Cai1, Nicole A Schneck1, Doug Harris1, Daniel Blackstock1, Vera B Ivleva1, Kuang-Chuan Cheng1, Adam Charlton1, Frank J Arnold1, Jonathan W Cooper1, Q Paula Lei2.   

Abstract

During research of a broadly neutralizing antibody (bNAb) for HIV-1 infection, site-specific clipping was observed during cell culture incubation. Protease inhibitor, 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), was supplemented to the cell culture feeding to mitigate clipping as one of the control strategies. It led to the need and development of a new assay to monitor the free AEBSF-related impurities during the purification process. In this work, a reversed-phase liquid chromatography (RPLC-UV) method was developed to measure the total concentration of AEBSF and its major degradant product, 4-(aminoethyl) benzenesulfonic acid (AEBS-OH). This quantitative approach involved hydrolysis pre-treatment to drive all AEBSF to AEBS-OH, a filtration step to remove large molecules, followed by RPLC-UV analysis. The method was qualified and shown to be capable of measuring AEBS-OH down to 0.5 μM with good accuracy and precision, which was then applied for process clearance studies. The results demonstrated that a Protein A purification step in conjunction with a mock ultrafiltration/diafiltration (UF/DF) step could remove AEBSF-related impurities below the detection level. Overall, this study is the first to provide a unique approach for monitoring the clearance of free AEBSF and its related degradant, AEBS-OH, in support of the bNAb research. Published by Elsevier B.V.

Entities:  

Keywords:  AEBS-OH; AEBSF; Antibody; Clipping; Impurity; Protease inhibitor; RPLC-UV; Residual

Mesh:

Substances:

Year:  2019        PMID: 30953918      PMCID: PMC7439605          DOI: 10.1016/j.jchromb.2019.03.022

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  14 in total

1.  Serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) inhibits the rat embryo implantation in vivo and interferes with cell adhesion in vitro.

Authors:  Ya-hong Jiang; Yan Shi; Ya-ping He; Jing Du; Run-sheng Li; Hui-juan Shi; Zhao-gui Sun; Jian Wang
Journal:  Contraception       Date:  2011-05-08       Impact factor: 3.375

2.  A companion protease inhibitor for the protection of cytosol-targeted recombinant proteins in plants.

Authors:  Charles Goulet; Meriem Benchabane; Raphaël Anguenot; France Brunelle; Moustafa Khalf; Dominique Michaud
Journal:  Plant Biotechnol J       Date:  2009-12-28       Impact factor: 9.803

3.  Overview of approaches to preventing and avoiding proteolysis during expression and purification of proteins.

Authors:  Barry J Ryan; Gary T Henehan
Journal:  Curr Protoc Protein Sci       Date:  2013-02

Review 4.  Trends in Upstream and Downstream Process Development for Antibody Manufacturing.

Authors:  Petra Gronemeyer; Reinhard Ditz; Jochen Strube
Journal:  Bioengineering (Basel)       Date:  2014-10-01

5.  Hydrolysis-Kinetic Study of AEBSF, a Protease Inhibitor Used during Cell-Culture Processing of the HIV-1 Broadly Neutralizing Antibody CAP256-VRC25.26.

Authors:  Jesse L Huang; Attila Nagy; Vera B Ivleva; Daniel Blackstock; Frank Arnold; Cindy X Cai
Journal:  Anal Chem       Date:  2018-03-13       Impact factor: 6.986

6.  Research and development of therapeutic mAbs: An analysis based on pipeline projects.

Authors:  Xiaomei Geng; Xiangjun Kong; Hao Hu; Jiayu Chen; Fengqing Yang; Hongyu Liang; Xin Chen; Yuanjia Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes.

Authors:  Abhinav A Shukla; Canping Jiang; Junfen Ma; Michael Rubacha; Lisa Flansburg; Steven S Lee
Journal:  Biotechnol Prog       Date:  2008-04-15

8.  Degradation of recombinant proteins by Chinese hamster ovary host cell proteases is prevented by matriptase-1 knockout.

Authors:  Holger Laux; Sandrine Romand; Sandro Nuciforo; Christopher J Farady; Joel Tapparel; Stine Buechmann-Moeller; Benjamin Sommer; Edward J Oakeley; Ursula Bodendorf
Journal:  Biotechnol Bioeng       Date:  2018-06-29       Impact factor: 4.530

9.  Potential effects of PKC or protease inhibitors on acute pancreatitis-induced tissue injury in rats.

Authors:  Changbin Shi; Xia Zhao; Xiangdong Wang; Liming Zhao; Roland Andersson
Journal:  Vascul Pharmacol       Date:  2007-02-13       Impact factor: 5.773

10.  Three unrelated protease inhibitors enhance accumulation of pharmaceutical recombinant proteins in Nicotiana benthamiana.

Authors:  Friederike Grosse-Holz; Luisa Madeira; Muhammad Awais Zahid; Molly Songer; Jiorgos Kourelis; Mary Fesenko; Sabrina Ninck; Farnusch Kaschani; Markus Kaiser; Renier A L van der Hoorn
Journal:  Plant Biotechnol J       Date:  2018-05-24       Impact factor: 9.803

View more
  2 in total

1.  Characterization of AEBSF-antibody modifications for a protease inhibitor supplementation strategy.

Authors:  Cindy X Cai; Nicole A Schneck; Weidong Zhao; Daniel Blackstock; Jiayan Cai; Doug Harris; Vera B Ivleva; Deepika Gollapudi; Joe Horwitz; Frank J Arnold; Jonathan W Cooper; Q Paula Lei
Journal:  Anal Bioanal Chem       Date:  2019-08-01       Impact factor: 4.142

2.  Quantification of residual hydrophobic fusion peptide with monomer and dimer forms using reversed-phase liquid chromatography.

Authors:  Cindy X Cai; Nicole A Schneck; Vera B Ivleva; Krishana Gulla; Yaqiu Zhang; Daniel Gowetski; Q Paula Lei
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2020-03-19       Impact factor: 3.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.